Objective. We assessed the relationship between sarcopenic obesity (SO) and metabolic syndrome (MetS) in Japanese elderly.
Introduction
Age-related changes in body composition are characterized by loss of skeletal muscle mass, termed sarcopenia, and gain in fat mass 1, 2) . Sarcopenia is a geriatric syndrome, and its association with frailty has been a focus of research 3) . Obesity accompanied with aging is characterized by central adiposity and ectopic fat deposits. Because sarcopenia and obesity both are associated with adverse health outcomes in the elderly 4) , sarcopenic obesity (SO), which is coexistence of sarcopenia and obesity, seems to be a more serious condition because of its poor outcomes, such as higher risks of disability 5, 6) , cardiovascular diseases 7) , metabolic disorders 8) , and mortality 9) .
Because of a lack of consensus, different definitions for SO have been used in various studies 10, 11) . Recently, the Asian Working Group for Sarcopenia (AWGS) declared the regional consensus guidelines for sarcopenia in the Asian elderly, and the diagnostic cutoff points for height-adjusted skeletal muscle mass measured using dual-energy X-ray absorptiometry (DXA) were advocated 12) . Since then, many researches on sarcopenia from
Asian countries have been reported 13) . However, research on SO using the AWGS consensus is lacking. In the present study, we evaluated the relationship between SO defined by the AWGS criteria and metabolic syndrome (MetS) among the Japanese elderly who underwent a comprehensive health checkup. . Blood pressure was measured on the right upper arm using an automatic device (BP-900; TANITA Corporation, Tokyo, Japan), which works on the combination of the Korotkoff sound method and oscillometric technique, after subjects had rested for at least 5 min in a sitting position at the hospital. Appendicular skeletal muscle mass (ASM) and total-body fat mass (FM) were measured using DXA (LUNAR PRODIGY series X-ray bone densitometer; GE Healthcare Japan Corporation, Tokyo, Japan), and visceral fat area (VFA) and abdominal circumference (AC) was measured using computed tomography (Aquilion CXL; Toshiba Medical Systems Corporation, Tochigi, Japan) using a single slice at the umbilical level. Skeletal muscle mass index (SMI) was calculated as ASM (kg) divided by the squared body height (m 2 ). The percentage of FM was calculated as FM (kg) divided by the body weight (kg) multiplied by 100.
Materials and Methods

Subjects
Blood chemistry measurements
Blood samples were collected after overnight fasting and immediately examined using an automatic biochemical analyzer (LABOSPECT008; Hitachi High-Technologies Corporation, Tokyo, Japan) at the central laboratory.
Other clinical data
Clinical data were extracted from the results of the comprehensive health checkups and included data related to age, sex, fasting plasma glucose (FPG) level, hemoglobin A1c (HbA1c) level, total cholesterol level, triglycerides (TG) level, high-density lipoprotein cholesterol (HDL-C) level, low-density lipoprotein cholesterol (LDL-C) level, and high-sensitivity C-reactive protein (hsCRP) level. Life-style habits, such as current smoking, current drinking, and regular exercise, and medical histories were obtained from self-reported questionnaires. Drinking habit was defined as "consumption of more than 40g of alcohol at least three times a week," and exercise habit as "daily walking activity for at least 1 h" or "performing daily exercise with mild sweating for more than 30 min at least twice a week." Definition of sarcopenia, obesity, and sarcopenic obesity According to AWGS criteria 12) , we used SMI cutoff points of <7.0 kg/m 2 for men and <5.4 kg/m 2 for women to diagnose sarcopenia. Regarding obesity, we used %FM cutoff points of ≥25% for men and ≥ 30% for women 14) . Participants who met the criteria for both definitions were defined as SO. According to these definitions, participants were classified into four phenotypes of body composition: standard, sarcopenia (without obesity), obesity (without sarcopenia), and SO ( Fig. 1) .
Definition of metabolic syndrome at-risk
To identify MetS at-risk, we used the diagnostic criteria of MetS defined by the Japanese Society of Internal Medicine 15) . In addition to central obesity defined by VFA ≥ 100 cm 2 in both sexes, the presence of at least one of the following three metabolic disorders indicated MetS at-risk: (1) systolic blood pressure ≥ 130 mmHg and/or diastolic blood pressure ≥ 85 mmHg or taking antihypertensive medicines, (2) TG 150 ≥ mg/dL and/or HDL-C < 40 mg/dL, or taking lipid-lowering medicines, and (3) FPG ≥ 110 mg/dL, or taking hypoglycemic medicines. Statistics Continuous variables were expressed as mean ± standard deviations, and categorical variables were presented as counts and percentages. Comparisons between men and women were analyzed using the unpaired Student's t-test; comparisons among four body composition phenotypes were analyzed using one-way analysis of variance, followed by the Scheffé test for multiple comparisons. Multivariate logistic regression analyses were performed to identify the risk for MetS associated with SO. The following explanatory variables were included in the models: age, sex, BMI, and smoking habits (0,1); drinking habits (0,1); and exercise habits (0,1). A value of p < 0.05 (two sided) was considered significant. Data were analyzed using IBM SPSS Statistics version 22 for Windows (IBM Japan, Tokyo, Japan).
Results
Characteristics of participants
The baseline characteristics of the participants are shown in Table 1 . Although BMI, VFA, and AC were higher in men than Fig. 1 The classification of body composition phenotypes SMI cutoff points of < 7.0 kg/m 2 for men and < 5.4 kg/m 2 for women were used to diagnose sarcopenia, and %FM cutoff points of ≥ 25% for men and ≥ 30% for women were used to diagnose obesity. Those who met the criteria for both definitions were defined as SO. Abbreviations: SO, sarcopenic obesity; SMI, skeletal muscle mass index; %FM, percentage of total-body fat mass. in women, almost all the participants fell within the standard range for BMI. Men had higher FPG, HbA1c, and TG levels and a lower HDL-C level than women. The prevalences of hypertension and dyslipidemia were 33% and 28%, respectively, and the prevalence of diabetes mellitus was 14%. None of the men or women had serious metabolic disorders. Regarding body composition, ASM and SMI were higher in men and %FM was higher in women.
Regarding body composition phenotypes, 31% of all the participants had a standard body composition, 20% of the participants had sarcopenia, 31% had obesity, and 18% had SO. The distributions of the four phenotypes of body composition were similar for both men and women.
The prevalence of MetS at-risk was 31% in all the participants, and it was significantly higher in men than in women (42% in men and 24% in women, p < 0.05).
Comparison of clinical parameters among the four phenotypes of body composition
Compared with the standard phenotype, BMI was higher among obese subjects and lower among subjects with sarcopenia, whereas, no significant difference in BMI was observed between subjects with standard body composition and those with SO. AC was the lowest among subjects with sarcopenia and gradually increased in accordance with the body composition phenotypes. As expected, a higher amount of VFA was observed in the obese and SO groups, accompanied by a higher prevalence of MetS at-risk, higher homeostasis model assessment of insulin resistance (HOMA-R), and higher TG and lower HDL-C levels than the corresponding values seen the subjects with the standard phenotype or sarcopenia alone ( Table 2) . HbA1c, hemoglobin A1c; HOMA-R, homeostasis model assessment of insulin resistance; TC, total cholesterol; TG, triglycerides; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; hsCRP, high sensitivity C-reactive protein; ASM, appendicular skeletal muscle mass; SMI, skeletal muscle mass index; FM, total-body fat mass.
Multivariate logistic regression analyses
To determine the relationship between SO and MetS at-risk, multivariate logistic regression analyses were performed. As shown in Table 3 , the subjects with obesity or SO were associ- 
Discussion
The present cross-sectional study assessed the relationship between SO and MetS among elderly subjects who had completed comprehensive health checkups. As a result, SO was found to be correlated with the risk for MetS, independently of the BMI and other confounders. To the best of our knowledge, this is the first report to evaluate the relationship between SO and MetS in elderly Japanese subjects.
Definition of sarcopenic obesity
Several definitions of sarcopenia and obesity have been reported previously 10, 11) . Baumgartner 16) first proposed the use of height-adjusted muscle mass using DXA for the diagnosis of sarcopenia, and the total-body fat percentage for the diagnosis of obesity. They demonstrated the strongest association of SO with physical disabilities. Another study assessed skeletal muscle mass using bioelectrical impedance analysis and also assessed muscle strength using grip power to define sarcopenia, while waist circumference was used to assess abdominal obesity 7) . It was found that SO, based on muscle strength but not muscle mass, was modestly associated with an increased risk of cardiovascular disease. Recently, the AWGS proposed diagnostic criteria of sarcopenia for elderly Asian population 12) . According to the AWGS criteria, sarcopenia is diagnosed by not only low muscle mass (SMI < 7.0 kg/m 2 for men and <5.4 kg/m 2 for women) but also low muscle strength (grip power <26 kg for men and < 18 kg for women). Muscle strength is considered as an index of muscle quality, and cumulative evidence has supported the importance of evaluations of both muscle mass and muscle strength to predict adverse effects on health such as functional decline 17) and mortality 18, 19) . Unfortunately, muscle strength, such as grip power, was not routinely examined in the comprehensive health checkup; therefore, we used only SMI cutoff points determined by AWGS to define sarcopenia.
The indices for the definition of obesity also varied among studies, some used BMI 20, 21) , while others used total-body fat percentage 5, 6, 16, 17, 22) , waist circumference 7, 9) , or visceral fat area 8, 23) . Regarding BMI, obesity is defined as BMI ≥25 kg/m 2 in Japanese adults. Although BMI is an easy, simple, and popular index for obesity, it is difficult to distinguish between fat mass and muscle mass 2) ; therefore, obesity and sarcopenia could be misclassified using the BMI definition. Alternatively, total-body fat percentage seems to be a preferable index to assess obesity in elderly people, who may have accumulated ectopic adipose tissue, such as visceral fat and intramuscular fat tissue.
Because of the various definitions of SO, the prevalence of SO also varies among studies. According to a recent review article 24) , the prevalence of SO in older adults ranges from 0% to 25%. This disparity might be due to differences in the study populations, including race and age distributions, in addition to the different definitions. Kohara et al. 23) examined elderly Japanese subjects who underwent medical checkups and reported that the prevalence of SO was 26.6% in men and 19.9% in women. These results are consistent with the prevalences of SO reported in the present study.
Sarcopenic obesity and metabolic syndrome
In the multivariate logistic regression analyses, the high OR for the risk for MetS seen in Model 1 in the obesity phenotype disappeared after adjustments for BMI and lifestyle factors (Model 2). In contrast, significant association between the SO phenotype and the risk for MetS seen in Model 1 remained marginal after further adjustments in Model 2. These results suggest that a coexistence of sarcopenia and obesity may have additive adverse effects on the development of metabolic disorders in the elderly.
Several studies from Asian countries have reported an association between SO and MetS 8, [20] [21] [22] . Despite using different definitions of sarcopenia and obesity, these reports concluded that SO seems to be a potent risk factor for MetS, compared with sarcopenia or obesity alone.
Insulin resistance is a major underlying pathology of MetS. It has been postulated that age-related intramuscular fat infiltration causes insulin resistance based on mitochondrial dysfunction 25, 26) . Chronic inflammation is another possible mechanism linking SO and MetS. It has been reported that obesity and inflammation are associated with the presence of MetS 27, 28) . Visceral adipose tissue is a source of inflammatory adipokines, such as interleukin (IL)-6 and tumor necrosis factor (TNF)-α, which are associated with both increased fat mass and decreased muscle mass 29) , and the acceleration of muscle catabolism may exacerbate insulin resistance. In the present study, hsCRP was the only inflammatory biomarker that was examined. No significant differences in the hsCRP level were observed between the SO group and the other phenotypes of body composition. The positive association of SO to MetS at-risk remained after further adjustment with hsCRP in Model 2 (OR, 3.04; 95% CI, 0.99 -9.24, p = 0.05).
The underlying pathogenesis linking SO and MetS
It has been postulated that age-related changes of body composition, that is, reduced muscle mass and increased fat mass, are strongly connected each other, and multiple interactions between muscle and adipose tissue along with aging may exacerbate insulin resistance 10, 30) . For example, sedentariness and lower physical activity seen in the elderly people may lead to muscle mass decline and muscle weakness, decreased endurance, reduced total energy expenditure, and fat gain 10) . Increased adipose tissue, particularly visceral adipose tissue, may lead to increased secretion of pro-inflammatory cytokines and adipokines, such as IL-6, TNF-α, and leptin 10) . Besides further increase of chronic lowgrade inflammation, which may exacerbate insulin resistance as mentioned above, increased leptin may lead to leptin resistance, as a result of a reduction of fatty acid oxidation in muscles which contributes to ectopic fat deposition. Ectopic intramuscular fat infiltration may affect muscle quality 10, 31) . Therefore, a vicious circle between muscle loss and fat gain along with aging may lead to more SO and metabolic disorders in the elderly people. Interestingly, a recent study suggested that metabolic disorders linked to SO may appear in the early stages of aging process, and that insulin resistance may act not only as a risk factor for cardiometabolic disorders but as an additional factor accelerating age-related muscle mass decline by interfering with protein metabolism 32) . Further researches are needed in order to explore underlying pathogenesis between SO and MetS.
Limitations
Several limitations of the present study must be mentioned. First, participants of this study were examinees from comprehensive health checkups who might be more health conscious. Therefore, our results may not be representative of the general population. Second, because of its cross-sectional, observational nature, causal relationships between SO and MetS cannot be determined. Third, in this study, we evaluated only muscle mass and did not examine physical performance or muscle strength, such as walking speed and grip power, which are important components for diagnosis of sarcopenia. Finally, we could not assess the biological pathway linking SO and MetS. Further studies should be prompted to evaluate mechanisms underlying age-related changes in body composition and metabolic disorders. Researches on ectopic adipose tissue, especially intramuscular fat, inflammatory biomarkers and adipokines, such as IL-6, TNF-α, and leptin, might benefit this issue.
Conclusions
In conclusion, the present study examined the relationship between age-related changes in body composition and the risk for MetS among the Japanese elderly who underwent comprehensive health checkups. As a result, SO had a greater association with the risk for MetS than obesity alone, independent of BMI and life style factors. From a practical perspective, age-related changes in body composition should be carefully considered when assessing health checkup data and advising older examinees on health education in the clinical setting.
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